Sharps Technology, Inc. Pitch Deck (2023) Breakdown

Sharps Technology, Inc. uses this October 2023 presentation to detail its evolution from a 2017 startup to a Nasdaq-listed medical device manufacturer. The core value proposition rests on the acquisition of the InjectEZ facility and a subsequent 10-year, $400 million purchase agreement with Nephron Pharmaceuticals. The deck emphasizes technical superiority in copolymer prefillable syringes (PFS) over traditional glass, citing benefits like high break resistance and improved drug stability. With a leadership team boasting deep experience at Merck and Baxter, Sharps positions itself as a high-g…

Key takeaways

• The company secured a 10-year purchase agreement for over $400 million from Nephron Pharmaceuticals (Slide 4).
• Sharps completed its IPO in April 2022, raising $16 million to fund its growth strategy (Slide 4).
• The product line focuses on copolymer prefillable syringes (PFS) which offer glass-like transparency with high break resistance (Slide 7).
• A comprehensive patent list includes 21 entries across the US, Japan, Europe, Australia, and Canada (Slide 16).
• The leadership team includes a Chairman who was a former Merck President with P&L responsibility for $10 billion (Slide 19).
• Revenue is projected to reach $45 million per year starting in 2025 through 2033 (Slide 22).
• The acquisition of the InjectEZ facility for $50 million is supported by a term sheet for up to $75 million in debt financing (Slide 22).

Frequently asked questions

What is the primary revenue driver for Sharps according to the deck?

The primary driver is a 10-year, $400 million purchase agreement with Nephron Pharmaceuticals. This deal is expected to generate approximately $30 million in revenue during the first twelve months following the Q1 2024 launch, scaling to $45 million annually from 2025 through 2033. This agreement is tied to the acquisition of the InjectEZ manufacturing facility.

How does Sharps differentiate its syringe technology from competitors?

Sharps focuses on 'specialty copolymer' prefillable syringes. Unlike traditional glass syringes, these polymer systems offer high break resistance, a strong moisture barrier, and no alkali, which improves drug stability. The deck notes that these systems are designed to work on existing 'fill-finish' pharma technology, reducing the barrier to adoption for major pharmaceutical companies.

What is the company's current manufacturing footprint?

Sharps operates an ISO-certified, CE-Mark approved, and FDA-cleared manufacturing facility in Hungary, acquired in July 2022. Additionally, the company signed an agreement in September 2023 to acquire the InjectEZ facility, which provides the capacity needed to fulfill the $400 million Nephron contract and serve the broader healthcare market.

Who are the key members of the leadership team?

The team is led by CEO Robert Hayes, who has 25 years of experience including roles at Baxter and Gerresheimer. The Chairman, Soren Bo Christiansen, MD, is a former President at Merck with experience managing $10 billion in business. The team also includes CFO Andrew Crescenzo, CPA, and CMO Steven Hertz, MD, providing a mix of clinical, financial, and operational expertise.

What is the status of the company's intellectual property?

Sharps holds a robust IP portfolio, as evidenced by Slide 16, which lists 21 patent filings. These cover needle and syringe systems with automatic safety shields and ultra-low-waste designs. The patents are at various stages, with several 'Active' status filings in the United States, Australia, and Canada, and others 'Pending' in Japan and Europe.

Sharps Technology, Inc. pitch deck: the facts

Company

Sharps Technology, Inc.

Year

2023

Stage

Public (Nasdaq: STSS)

Slides

22

Sector

Medical Device Manufacturing

Deck type

Investor Presentation

Outcome

Active / Publicly Traded

Headquarters

United States

Sharps Technology, Inc. pitch deck PDF

The full Sharps Technology, Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Sharps Technology, Inc. pitch deck was used for

This deck is an October 2023 investor presentation for Sharps Technology, Inc. (Nasdaq: STSS), a publicly listed medical device and pharmaceutical packaging company focused on safety syringes and prefillable syringe systems. It was presented after the company’s April 2022 IPO and during its transition from primarily R&D into scaled commercialization using a manufacturing facility in Hungary and a planned U.S. facility acquisition. The presentation centers on a large multi‑year syringe supply agreement and the planned acquisition of the InjectEZ manufacturing facility in South Carolina, positioning Sharps to expand capacity in copolymer prefillable syringes. As a public‑company investor deck, it is aimed at equity investors rather than a private fundraise, likely supporting broader capital markets access and future financing flexibility rather than a specific disclosed round.

Business model: Sharps Technology, Inc. is a medical device and pharmaceutical packaging company focused on patented smart‑safety syringe products and specialty copolymer prefillable syringe systems for healthcare and pharmaceutical markets.

Founded

2017

Headquarters

105 Maxess Road, Suite 124, Melville, New York 11747, United States

Industry

Medical Instruments & Supplies / Medical Device & Pharmaceutical Packaging

What happened after the Sharps Technology, Inc. deck

By and after the time of the October 2023 investor presentation, Sharps Technology had transitioned from R&D focus into early commercialization of patented safety syringe and copolymer prefillable syringe products, supported by a high‑capacity Hungary manufacturing facility and plans to acquire the InjectEZ South Carolina facility to fulfill large multi‑year supply agreements. Subsequent disclosur

• Sharps Technology completed its IPO and listing on Nasdaq under the symbol STSS (with warrants STSSW) in April 2022, est
• The company operates an ISO‑certified, FDA‑registered syringe manufacturing facility in Hungary with up to 500 million u
• Sharps entered into significant multi‑year commercial agreements, including previously disclosed sales contracts such as
• Public updates indicate that Sharps has positioned itself to address supply‑chain disruptions caused by FDA recalls, war
• Later communications report that Sharps completed an exit from legacy syringe manufacturing and introduced a Solana‑base

What the Sharps Technology, Inc. deck got right

• Clear focus on patented smart‑safety syringe technology with ultra‑low waste features. Sharps Technology’s decks consistently highlight a portfolio of patented smart‑safety syringe products (Securgard, Sologard, Sharps Provensa) designed for ultra‑low waste drug delivery and integrated passive and active safety mechanisms, providing a clear technological differentiation narrative in a commoditized syringe market.
• Anchoring the story in long‑term commercial contracts and strategic partnerships. The October 2023 deck emphasizes a large 10‑year syringe supply agreement and partnerships such as the manufacturing and sales collaboration with Nephron Pharmaceuticals, tying Sharps’ specialized products directly to long‑term, high‑value commercial relationships.
• Strong manufacturing infrastructure with clear capacity and regulatory credentials. Sharps Technology showcases an ISO‑certified, FDA‑registered manufacturing facility in Hungary with up to 500 million units annual capacity and plans to add a U.S. facility through the InjectEZ acquisition, supporting the deck’s claims about scalable global supply capabilities.
• Compelling narrative around next‑generation copolymer prefillable syringes. The deck positions Sharps as an innovator in copolymer prefillable syringe systems, a segment attractive to pharmaceutical companies seeking alternatives to traditional glass, and connects this to both the InjectEZ facility acquisition and large supply agreements, strengthening the future‑growth narrative.
• Effective framing as a solution to global syringe supply‑chain disruptions. By situating its strategy within broader supply‑chain disruptions caused by recalls, warnings, and tariffs on Chinese‑manufactured syringes, Sharps frames its manufacturing footprint and contracts as a timely solution to global reliability and quality concerns, which can resonate strongly with investors.
• Good alignment between deck claims and externally verifiable public information. Listing details, product descriptions, and manufacturing credentials in the deck are consistent with later SEC filings and third‑party profiles, which reinforces credibility and reduces concerns about misalignment between pitch content and public disclosures.

What could have been stronger

• Limited externally verifiable detail on the highlighted 10‑year supply agreement. The October 2023 investor deck heavily emphasizes a massive 10‑year syringe supply agreement and the planned InjectEZ facility acquisition, but publicly available filings and releases do not provide clear, independently verifiable quantitative details (exact volume, minimum purchase obligations, or guaranteed revenue) for that specific 10‑year contract beyond references to large multi‑year agreements such as a separate $50 million SoloGard sales agreement. This makes it difficult for investors to reconcile the deck’s long‑term revenue narrative with disclosed contractual specifics.
• Weak linkage between growth narrative and reported financial performance. While the deck positions Sharps as transitioning from R&D to scaled commercialization, contemporaneous and subsequent public financial data show very modest trailing‑twelve‑month revenue and continuing net losses, suggesting that near‑term financial performance remained constrained despite the growth story. Without explicit bridge metrics in the deck, investors may struggle to connect historic financials to the projected impact of the manufacturing expansion and supply agreements.
• Incomplete disclosure of U.S. facility acquisition terms and execution risks. External sources indicate that Sharps planned to acquire the InjectEZ syringe manufacturing facility in South Carolina and expand U.S. manufacturing capability, but public materials do not clearly spell out key transaction terms (purchase price, integration timeline, capital expenditure) or detailed contingency risks in the October 2023 deck. This leaves uncertainty around execution risk, financing needs, and the pace at which U.S. capacity would become fully productive.
• Strategic evolution after the deck not foreshadowed in the narrative. Later public communications describe strategic changes, including exiting legacy syringe manufacturing and introducing a digital asset treasury strategy around Solana, which represent material shifts from the October 2023 deck’s focus on specialized syringe manufacturing and supply agreements. For an investor relying on the October 2023 deck alone, this potential for strategic pivot risk and business‑model evolution is not visible, limiting the deck’s usefulness for long‑term thesis evaluation.

How an investor would read this deck

What draws attention

• Verify the specific terms of the 10‑year syringe supply agreement highlighted in the October 2023 presentation, including minimum purchase commitments, pricing, termination clauses, and whether it is binding or subject to performance or regulatory milestones.
• Understand Sharps Technology’s roadmap for scaling capacity across its Hungary facility and the planned InjectEZ South Carolina facility, including capital expenditure requirements, regulatory approvals, and expected timelines to reach targeted output.
• Assess how the specialty copolymer prefillable syringe technology is differentiated (regulatory status, key IP, performance vs. incumbent glass prefillable syringes) and whether it can command premium pricing or sticky long‑term contracts.
• Reconcile the growth narrative around large supply agreements and expanded manufacturing with reported revenue, margins, and cash burn in SEC filings to gauge the realism of commercialization claims.
• Monitor subsequent strategic updates, including any exit from legacy syringe manufacturing and the integration of non‑core strategies such as digital asset treasuries, to understand how the investment case has evolved since the October 2023 deck.

Risks that stand out

• Execution risk around scaling manufacturing capacity in Hungary and the planned U.S. facility, including potential delays in regulatory approvals, equipment installation, and workforce ramp‑up that could affect the timing of fulfilling long‑term supply agreements.
• Customer concentration and contract risk if the highlighted 10‑year supply agreement and other multi‑year contracts represent a large share of expected revenue, exposing Sharps to renegotiation, non‑renewal, or performance‑related termination.
• Financial risk given historically low revenue and net losses, which may necessitate additional equity or debt financing and could dilute shareholders or constrain growth investments if capital markets are less receptive than anticipated.
• Strategic risk associated with shifting focus, such as exiting legacy syringe manufacturing and integrating a Solana‑based digital asset treasury strategy, which may introduce volatility and distract management from core medical device execution.
• Regulatory and market risk in the syringe and pharmaceutical packaging space, including FDA recalls, warnings, and tariffs on competing products, which can create both opportunities and uncertainties that require agile compliance and supply‑chain management.

Questions this deck invites

• What are the exact commercial terms, performance obligations, and risk‑allocation mechanics of the 10‑year syringe supply agreement referenced in the October 2023 investor presentation, and how much of that revenue is contractually committe
• What is the current regulatory and qualification status of the InjectEZ South Carolina facility (or its successor U.S. site), and what capital investments and timelines are required to bring it to full commercial capacity for copolymer pref
• How do Sharps Technology’s safety syringe products and copolymer prefillable syringes compare technically (e.g., dead‑space reduction, safety features, drug compatibility) and economically (unit costs, pricing, margins) versus leading incum
• How have revenue, gross margin, operating expenses, and cash runway evolved from 2022 through the periods following the October 2023 presentation, and what portion of reported revenue is attributable to large supply agreements such as the S
• What governance, risk‑management, and capital‑allocation frameworks are in place to oversee newer strategies such as exiting legacy manufacturing and adopting a digital asset treasury, and how do these strategies interact with the core medi

What founders can take from the Sharps Technology, Inc. deck

• A public‑company investor deck can effectively anchor its story around a few major commercial milestones, such as a long‑term supply agreement and a transformational manufacturing asset acquisition, to convey a clear path from R&D to commercialization.
• Highlighting specialized technology (e.g., copolymer prefillable syringes and ultra‑low waste safety syringes) tied directly to large contracts helps investors connect differentiated IP to tangible demand rather than abstract innovation.
• Positioning manufacturing assets with specific capacity figures and regulatory credentials (ISO, FDA, CE, WHO) gives credibility to claims of being able to fulfill large multi‑year agreements and address global supply‑chain disruptions.
• Investor presentations for public companies still benefit from clearly reconciling growth narratives with reported financials and SEC filings; when this bridge is thin, investors will need to do more independent verification.
• Subsequent strategic updates can diverge meaningfully from the story told in a specific deck, underscoring the importance of treating any pitch as a point‑in‑time snapshot rather than a static blueprint for the company’s long‑term trajectory.
• For companies in regulated healthcare markets, linking commercial plans explicitly to regulatory status of facilities and products (e.g., FDA registration, ISO certification) can strengthen investor confidence in execution feasibility.

Sharps Technology, Inc. pitch deck: common questions

What does Sharps Technology, Inc. do?

Sharps Technology, Inc. is a medical device and pharmaceutical packaging company that designs, develops, manufactures, and commercializes patented smart‑safety syringe products such as Securgard, Sologard, and Sharps Provensa, along with specialized copolymer prefillable syringe systems. Its products focus on ultra‑low waste drug delivery and features that prevent accidental needlestick injuries and syringe reuse.

Is Sharps Technology a public company and what is its ticker?

Sharps Technology is listed on Nasdaq under the ticker **STSS** for its common stock, with **STSSW** used for its publicly traded warrants. The company completed its initial public offering (IPO) on April 14, 2022.

What products and technologies are highlighted in Sharps Technology’s investor presentations?

Sharps Technology’s core products include the Securgard, Sologard, and Sharps Provensa smart safety syringes, which are ultra‑low waste syringes with passive and active safety mechanisms and reuse prevention features. In addition, the company develops and manufactures specialty copolymer prefillable syringe systems for pharmaceutical packaging and drug delivery.

Where does Sharps Technology manufacture its syringes, and what capacity does it have?

Sharps Technology operates an ISO‑certified and FDA‑registered syringe manufacturing facility in Hungary with annual capacity of up to 500 million units. In 2023–2024 the company emphasized a planned acquisition of the InjectEZ syringe manufacturing facility in South Carolina, USA, as part of its strategy to expand U.S. capacity for copolymer prefillable syringes.

What major commercial agreements are referenced in Sharps Technology’s October 2023 investor presentation?

Subsequent public communications describe large multi‑year supply agreements tied to Sharps’ SoloGard and other syringe lines, including previously disclosed agreements such as a $50 million SoloGard sales agreement. The October 2023 deck specifically highlights a massive 10‑year supply agreement and the InjectEZ facility acquisition to support that contract, but the full commercial and financial details of that 10‑year agreement are not independently quantified in public filings or releases beyond the existence of large multi‑year contracts.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• Sharps Investor Presentation October 2023
• Sharps Technology Inc, STSS:NAQ profile - FT.com
• 0
• Sharps Technology (STSSW) Company Profile & Description
• PowerPoint Presentation
• [PDF] Form 10-K for Sharps Technology INC filed 03/29/2024
• Profile
• Sharps Technology, Inc. Information

Sharps Technology, Inc. pitch deck slides

What each slide of the Sharps Technology, Inc. pitch deck says

Slide 1

Collaboration. | | | pl I Innovation. | hla BEL Novel Technology. 3 § , Making the World a i Healthier Place. § | < - r Investor Presentation October 2023 | Nasdaq: STSS ©2023 Sharps Technology, Inc. All rights reserved.

Slide 2

| Transformative Deal with Nephron Announced 9/26/23 Pending Acquisition of InjectEZ and $400M 10-Year Supply Agreement Strengthens Path Forward > Signed asset purchase agreement on September 26, 2023 to acquire InjectEZ specialty copolymer syringe manufacturing facility and a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals » Transformative acquisition and purchase agreement enables Sharps to commercialize its innovative copolymer prefillable syringe systems to the healthcare market for the first time > Nephron commits to minimum orders of over $400 Million over 10 years + Product delivery is scheduled for the first quarter of 2024 + Revenue totaling approximat…

Slide 3

Nephron Pharmaceuticals Privately Held World Leader with Over 26 Years of Experience in Contract Manufacturing, 503B Outsourcing, Respiratory Medication Production, and Product Enhancements that Promote Safety Key Highlights: > Recently celebrated a successful $350 million capital raise led by BlackRock Capital Investment Advisors and PNC Bank, National Association (PNC) to support future growth » Significant contract manufacturing business elected as the primary supplier by Abbott Labs for Rapid Covid-19 Test Kits, hiring ~1,500 additional employees through the process » Large privately held conglomerate with clients across leading healthcare/pharmaceutical companies » World's largest blow…

Slide 4

| Significant Developments » Founded in 2017 with a vision to develop innovative drug delivery technology for the healthcare industry + Developed strong product line of patented smart safety syringe systems » Products are FDA, WHO and CE Mark approved and cleared for use by Pfizer and Moderna + Sharps prefillable syringe (PFS) systems will be launched in Q1 of 2024 through the Nephron transaction » September 2021: Sharps names Robert Hayes as CEO «Primary driver for signing recent deal with Nephron * 25years' experience in the healthcare, medical device, and pharmaceutical manufacturing industry + Senior positions at Gerresheimer Pharmaceutical Glass (11 years) and positions at Baxter Healt…

Slide 5

— =o ae — -F = ’ ml L | | | i — URE | Prefillable Advanced § I FS = | Polymer Syringes = 5 1 designed for current re fill finish lines p- SHARPS Fshampe Prefillable Syringes

Slide 6

| Medical Syringe Market Overview + Syringes are classified into two main groups: + Prefillable syringes: Made of plastic, are filled and stored like vials and disposed of after use + Disposable syringes: Provide an efficient and user-friendly method of single use drug delivery + The market for syringes is currently growing at 4x GDP «Market is increasing due to a steady growth in the number of insured aging people with medical needs + The largest therapeutic areas for prefilled syringes are oncology, followed by diabetes, rheumatoid arthritis, and multiple sclerosis + Innovations in self-administered drug delivery devices such as Sharps’ syringes + Patients’ preference to accept treatment…

Slide text above is read directly from the Sharps Technology, Inc. deck PDF embedded on this page.

Related fundraising guides (24)

• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Arkestro Pitch Deck Teardown: A Masterclass in Social Proof and Domain Authority
• HMNC Brain Health Pitch Deck Teardown: A Precision Psychiatry Play for Depression
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• Condense Pitch Deck Teardown: Solving the 'Pre-Recorded' Problem in Metaverse Live Events
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• Craft.io Pitch Deck Teardown: A $8M Series A Masterclass in Product-Led Narrative
• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Alcatraz AI Pitch Deck Teardown: Leveraging Apple FaceID Pedigree for Enterprise Security
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Ideon Technologies Pitch Deck Teardown: Using Muon Tomography to De-Risk Mining Exploration
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods

Decks from the same year (1)

• 2023 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with S

More pitch deck teardowns (16)

• SHAFOO Pitch Deck Teardown: Incentivizing Food Waste Reduction via Social Loyalty
• Shakr Pitch Deck Breakdown: Solving the SMB Video Ad Creative Gap
• Shapes Pitch Deck Teardown: A Modular Approach to AI-Native HR Automation
• Sharebee Pitch Deck Breakdown: A Visual-First Approach to Peer-to-Peer Storage
• Sharesomestyle Pitch Deck Breakdown: A Visual-First Approach to Personal Styling Marketplaces
• Shares Pitch Deck Teardown: A $40M Series B Masterclass in Social Proof and Momentum
• Sharpist Pitch Deck Breakdown: Scaling Enterprise Coaching to a $23M Series A
• Sharps Technology Pitch Deck Teardown: A Micro-Cap Public Company's Path to Commercialization
• Shearshare Pitch Deck Teardown: A Masterclass in Demo Day Efficiency and Unit Economics
• Sheena Allen Apps Pitch Deck Teardown: Leveraging a 1.4M Download Track Record for PicSubject
• SheNative Pitch Deck Teardown: A Social Enterprise Model for Indigenous Fashion
• Sherpa Pitch Deck Teardown: A B2B Travel API Play for Global eVisa Infrastructure
• Shipium Pitch Deck Teardown: Leveraging Amazon-Grade Pedigree for a $27.5M Series A
• Shiplyst Pitch Deck Breakdown: A Lean 9-Slide Case for Indian Freight Digitization
• Shippo Pitch Deck Breakdown: The Power of Minimalist Traction Metrics
• Shiva Pitch Deck Teardown: The $10M Pre-Seed Bet on AI Micro-Startups

Recently published pitch deck teardowns (12)

• Boom Pitch Deck Teardown: A Masterclass in Unit Economics and Strategic Investor Social Proof
• Brigad Pitch Deck Teardown: A Mission-Driven Approach to the €1,000bn Flexible Labour Market
• CAMP4 Therapeutics Pitch Deck Teardown: A $100M Masterclass in Biotech Platform Validation
• Cann Pitch Deck Teardown: Positioning Cannabis as a Mainstream Alcohol Alternative
• Catch+Release Pitch Deck Teardown: Solving the Legal Bottleneck of User-Generated Content
• Carta Healthcare Pitch Deck Teardown: Scaling Clinical Data Abstraction with Human-in-the-Loop AI
• Capalo AI Pitch Deck Teardown: Optimizing Virtual Power Plants with AI-Driven Trading
• Chef Robotics Pitch Deck Teardown: A Data-First Approach to Solving Food Labor Shortages
• Cerebrium Pitch Deck Teardown: Selling Efficiency in the High-Stakes GPU Arms Race
• Ciroos Pitch Deck Teardown: A $21M Seed Round Built on Deep Domain Expertise
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• Checkstep Pitch Deck Teardown: A 7-Slide Product Showcase for AI Content Moderation

Fundraising library · Pitch deck examples · Investor directory · Founder database